Biocept

Biocept Share Buybacks

Delisted

The Share Buybacks of Biocept (BIOC) as of Nov 3, 2026 is 26.60 M USD. In the previous year, Share Buybacks was 30.60 M USD — a change of -13.07% (lower).

Share Buybacks

26.60 MUSD

YoY

-13.07%

Last updated:

Share Buybacks of Biocept is 2020 26.60 M USD. Share Buybacks of Biocept was 2019 30.60 M USD. It decreases by -13.07% lower compared to the previous year.

The Biocept Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2014
17.39 M USD
Jan 1, 2015
19.55 M USD
Jan 1, 2016
13.77 M USD
Jan 1, 2017
21.00 M USD
Jan 1, 2018
25.69 M USD
Jan 1, 2019
30.60 M USD
Jan 1, 2020
26.60 M USD
The Biocept Share Buybacks history
YEARShare BuybacksYoY
26.60 MUSD-13.07%
30.60 MUSD+19.07%
25.69 MUSD+22.33%
21.00 MUSD+52.52%
13.77 MUSD-29.55%
19.55 MUSD+12.41%
17.39 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

Share Buybacks of Biocept is 26.60 M USD in 2020.

Share Buybacks of Biocept changed from 30.60 M USD to 26.60 M USD, representing a -13.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks Biocept since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Biocept historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biocept

All Key Metrics — Biocept